Aldijana Sacic
Psychiatric/Mental Health · Saint Louis, MONPI 1740807825
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $405,664 of the $510,250 with a category attached, or 79.5%. Neurocrine Biosciences, Inc. accounts for 61.6% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $247,843, more than ten times the $1,842 reported in 2021. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 764 payments — averaging $667.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$314K
- Johnson & Johnson$156K
- Otsuka America Pharmaceutical, Inc.$37K
- Alkermes, Inc.$861
- Teva Pharmaceuticals USA, Inc.$672
- Acadia Pharmaceuticals Inc$335
- plus $1K from 15 others
What the payments were for
- Consulting fees$27,7515%
- Speaking & faculty fees$405,66480%
- Travel & lodging$59,74612%
- Food & beverage$17,0363%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 331 | $314,422 |
| Johnson & Johnson | 207 | $155,690 |
| Otsuka America Pharmaceutical, Inc. | 82 | $37,026 |
| Alkermes, Inc. | 21 | $861 |
| Teva Pharmaceuticals USA, Inc. | 34 | $672 |
| Acadia Pharmaceuticals Inc | 6 | $335 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $322 |
| Jazz Pharmaceuticals Inc. | 23 | $266 |
| Sun Pharmaceutical Industries Inc. | 12 | $117 |
| Neurelis, Inc. | 4 | $94 |
| Indivior Inc. | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| UCB, Inc. | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| AbbVie | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Merck | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$310,887
- INVEGA SUSTENNA$153,471
- INVEGA TRINZA$151,296
- REXULTI$36,104
- LYBALVI$940
- ARISTADA$884
- NUPLAZID$246
- ARISTADA INITIO$221
- CAPLYTA$125
- UZEDY$117
- ABILIFY ASIMTUFII$101
- ABILIFY MAINTENA$101
How this compares
$510,250 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 66 | $327,613 |
| RexultiBrexpiprazole | 116 | $174,423 |
| NuplazidPimavanserin Tartrate | 31 | $76,638 |
| Invega SustennaPaliperidone Palmitate | 18 | $53,132 |
| AristadaAripiprazole Lauroxil | 12 | $18,026 |
| TrintellixVortioxetine Hydrobromide | 44 | $17,916 |
| Paliperidone ErPaliperidone | 34 | $9,126 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,528 |
| Mirtazapine | 496 | $6,479 |
| Lurasidone Hcl | 19 | $4,699 |
| Prazosin Hcl | 384 | $3,856 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 159 | $3,636 |
| Divalproex Sodium | 70 | $3,615 |
| Clonazepam | 461 | $3,555 |
| Quetiapine Fumarate | 362 | $3,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $314,422 | $327,61366 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37,026 | $174,423116 claims |
| Acadia Pharmaceuticals IncNuplazid | $335 | $76,63831 claims |
| Johnson & JohnsonInvega Sustenna | $155,690 | $53,13218 claims |
| Alkermes, Inc.Aristada | $861 | $18,02612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $72 | $17,91644 claims |
| AbbVieNamzaric | $18 | $6,52812 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $2,405744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Saint Louis
- Julie WaterburySaint Louis$135K
- Melinda SmithSaint Louis$13K
- Richard YakimoSaint Louis$10K
- Yevgeniya MykhaylevskaSaint Louis$9K
- Anastasia AmiramovaSaint Louis$9K
- Jessica BurichSaint Louis$8K
- Jennifer ArmstrongSaint Louis$8K
- Bonnie HuffSaint Louis$7K
- Jacqueline KirkSaint Louis$6K
- Danielle RoncoSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.